Navigation Links
Sinobiopharma Announces 350% Increase in Production of Its Flagship Drug in the First Quarter of 2009 Over the Same Period in 2008
Date:5/14/2009

NANTONG CITY, China, May 14 /PRNewswire-FirstCall/ -- Sinobiopharma, Inc. (OTC Bulletin Board: SNBP) ("Sinobiopharma" or, the "Company") is pleased to announce that production of its flagship drug, Cisatracurium Besylate, increased by 350% in the first quarter of 2009 compared to production in the first quarter of 2008.

In response to a sharp rise in orders, Sinobiopharma increased the total output of the skeletal muscle relaxant to 214,900 units in the first quarter of 2009, compared to 47,700 units for the same period in 2008.

"We were able to achieve the dramatic rise in production despite the global economic crisis and challenges within the Chinese pharmaceutical industry," said Lequn Huang, Company President and CEO. "We anticipate that demand for our flagship product, and for our newly launched anti-hypertensive, Perindopril, will continue to grow. We also expect that this growth, and planned acquisitions in 2009, will drive a higher level of performance for Company this year."

Sinobiopharma distributes Cisatracurium Besylate in 30 provinces and key major cities throughout China through sales partners and other sales networks.

About Sinobiopharma

Sinobiopharma Inc. is a fully integrated and highly innovative biotechnology company engaged in the research and development, manufacture and marketing of biopharmaceutical products in China, the world's fastest growing pharmaceutical market. Known as Dong Ying (Jiangsu) Pharmaceutical Co. Ltd. in China, the Company's current therapeutic focus is on anesthesia-assisted agents and cardiovascular drugs.

FORWARD LOOKING STATEMENTS

This news release may include "forward-looking statements" regarding Sinobiopharma, Inc., and its subsidiaries, business and project plans. Such forward looking statements are within the meaning of Section 27A of the Securities Act of 1933, as amended, and section 21E of the United States Securities and Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor created by such sections. Where Sinobiopharma, Inc. expresses or implies an expectation or belief as to future events or results, such expectation or belief is believed to have a reasonable basis. However, forward-looking statements are subject to risks, uncertainties and other factors, which could cause actual results to differ materially from future results expressed, projected or implied by such forward-looking statements. Sinobiopharma, Inc. does not undertake any obligation to update any forward-looking statement, except as required under applicable law.


'/>"/>
SOURCE Sinobiopharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Sinobiopharma, Inc. Signs Sales Contract for Flagship Project
2. Sinobiopharma Reports Highlights of Third Quarter Results for Its Operating Subsidiary, Dong Ying China
3. China Sky One Medical, Inc. Announces Record First Quarter 2009 Results
4. Connectyx CEO Announces Support of the Obama Plan to Invest in Health Information Technology
5. Birner Dental Management Services, Inc. Announces Net Income up 31% for the Quarter
6. Duane Reade Announces Premier-Level Sponsorship of AIDS Walk New York
7. Concentric Medical Announces Enrollment Milestone for Merci Registry
8. Natural Alternatives International, Inc. Announces Fiscal 2009 Q3 Results
9. eDiets.com(R) Announces Q1 2009 Results
10. Misonix Announces Attendance at 22nd Annual Symposium on Advanced Wound Care
11. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2017)... ... July 28, 2017 , ... Lundquist Insurance Services, a family ... and families across east Texas, is embarking on a charity event in conjunction ... area. , America’s Mighty Warriors offers a series of programs for veterans that ...
(Date:7/28/2017)... ... 2017 , ... Leyden Insurance Agency, a Chicago based firm that offers asset ... County, is working in conjunction with the Conner T. Lowry Memorial Fund in a ... of a brave soldier who is still dearly missed by his community, the Connor ...
(Date:7/27/2017)... ... 2017 , ... Conventus, New Jersey’s premier professional liability insurer ... new educational series of webinars and podcasts to guide medical practices on understanding ... The first two episodes of the series, entitled “Pain Management and Opioids: New ...
(Date:7/27/2017)... (PRWEB) , ... July 27, 2017 , ... ... Diplomate of the American Board of Oral Implantology/Implant Dentistry (ABOI/ID). After successfully completing ... the nation’s leading providers of dental implants . Dr. Kimowitz and his ...
(Date:7/27/2017)... ... ... Standard Process is ushering in a new era of innovation with the ... (NCRC) in Kannapolis, North Carolina and by announcing a new leadership team, board and ... occupying over 10,000 square feet on the first floor of the David H. Murdock ...
Breaking Medicine News(10 mins):
(Date:7/26/2017)... Aesthetics, a leading medical aesthetic clinic in Singapore ... skin conditions from the inside. The natural process of ... skin becomes more transparent due to the thinning of the epidermis. Over ... the sun contributes to aging skin, causing age spots and other ... ...
(Date:7/25/2017)... BARCELONA, Spain and CAMBRIDGE, Massachusetts ... SOM Biotech, specializing in repurposing drugs to treat rare nervous ... Therapeutics Inc. to clinically develop and market the drug SOM0226 ... reached, the drug achieved very promising results in a Phase ... A new office in the United ...
(Date:7/24/2017)... -- Diplomat Pharmacy, Inc. (NYSE: DPLO ) announced ... operating results on Monday, August 7, 2017 after market ... p.m. ET. Shareholders ... of the conference call by dialing 877-201-0168 or 647-788-4901 ... 15 minutes prior to the call. A live webcast ...
Breaking Medicine Technology: